Lonza Group stock: CMS gets NeuroPortal license rights
Published on 11/17/2026 at 11:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNeuroPortal license expands commercial reach
- CMS secured exclusive global rights for up to two products targeting neurodegenerative diseases.
- Lonza will receive upfront, development and commercial milestone payments plus royalties on net sales.
- Further platform results are being presented at the PEGS summit in Lisbon through November 19.
On Tuesday, November 17, 2026, Lonza and China Medical System Holdings Limited announced a global exclusive license agreement for Lonza's NeuroPortal transferrin receptor 1 blood-brain barrier technology, according to BioSpectrum Asia. CMS secured exclusive global rights for up to two products targeting neurodegenerative diseases.
The agreement gives CMS access to NeuroPortal TfR1 technology, which is designed to help therapeutic molecules cross the blood-brain barrier. Lonza said the platform offers binding variants with different affinities, allowing developers to assess receptor engagement, transport across the barrier and brain exposure.
Payments depend on development success
Lonza will receive an upfront payment, development and commercial milestone payments, and royalties on net sales under the agreement. Financial amounts and milestone conditions were not disclosed. Lonza will continue to offer licensing rights for other therapeutic programs using the NeuroPortal TfR1 technology.
The platform's commercial potential is linked to the difficulty of delivering medicines to the central nervous system. BioSpectrum Asia reported that NeuroPortal outperformed a leading industry benchmark in preclinical studies both as an immunoglobulin G fusion and in combination with Lonza's GlycoConnect platform.
Peter Droc, Lonza's head of licensing, said the technology is intended to give developers flexibility to assess genetic-fusion and bioconjugation approaches. He described CMS's selection of the platform as an important step in its commercial development.
Results presented during Lisbon summit
Detailed results from Lonza's NeuroPortal TfR1 platform are being presented at the 18th annual Protein & Antibody Engineering Summit in Lisbon, Portugal, which runs from November 16 through November 19. The presentation schedule gives investors a near-term opportunity to assess the platform's preclinical evidence and development potential.
Lonza Group stock traded at 723.70 euros on Lang & Schwarz at 11:40 CET on Tuesday, November 17, 2026.
Lonza Group AG
- ISIN: CH0013841017
- Ticker: LONN.SW
- Quote: 723.70 euros on Lang & Schwarz at 11:40 CET on November 17, 2026
More news and analyses on Lonza Group stock
Switzerland's SMI provides the broader market backdrop for Swiss-listed shares.
